The court ruled that Cipla’s antibiotic name ‘FURIZOME’ is too similar to rival Adcock Ingram’s ‘URIZONE,’ citing a risk of ...

The Management has withdrawn the suspension of operations order and has instead declared lockout at Walchandnagar Industries ...

The 5-day simple moving average is Rs 1503.51. Cipla's stock is priced at Rs 1464.95, reflecting a notable daily change of 3.49%. Over the past three years, the company has delivered returns of 38.04% ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug ...

Cipla, a major player in the pharmaceutical industry, announced on Friday that it has received approval from the US Food and Drug Administration (USFDA) to market a generic cancer treatment drug. The ...

Cipla’s formulation is an AB-rated therapeutic equivalent of Abraxane and is indicated for the treatment of metastatic breast cancer, advanced or metastatic non-small cell lung cancer (NSCLC), and ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and ...

The drug is expected to launch in the US in the first half of the fiscal year. New Delhi, Apr 11 (PTI) Drug major Cipla on Friday said it has received approval from the US health regulator to market a ...

Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial.

Company has received final approval from USFDA for ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial ...

NEW DELHI, Apr 11: Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the ...

A view shows a Microsoft logo at Microsoft offices in Issy-les ... workforce composition and boost operational efficiency. The company has refused to comment on the speculations.